Efficacy of multiple balloon aortic valvuloplasty procedures  by Ferguson, James J. & Garza, Ricardo A.
1430 lACC Vol. 17, No.6 
May 1991:1430-5 
SEMINAR ON BALLOON AORTIC VALVULOPLASTY-VI 
William W. O'Neill, MD, FACC, Guest Editor 
Efficacy of Multiple Balloon Aortic Valvuloplasty Procedures 
JAMES J. FERGUSON, MD, FACC, RICARDO A. GARZA, MD AND THE MANSFIELD SCIENTIFIC 
AORTIC VALVULOPLASTY REGISTRY INVESTIGATORS 
To determine the efficacy of a second balloon aortic valvuloplasty 
procedure in comparison with the original procedure, 47 patients 
(18 men, 29 womenj mean age 77 ± 10 years) who underwent two 
balloon aortic valvuloplasty procedures over a mean interval of 
6.4 months between procedures (range 2 days to 15 months) were 
retrospectively examined. The mean pressure gradient across the 
aortic valve was significantly higher before the first than before 
the second valvuloplasty procedure (62 ± 21 vs. 53 ± 21 mm Hgj 
p < 0.05) and after the first compared with after the second 
procedure (32 ± 13 vs. 28 ± 14 mm Hgj p < 0.05). The cardiac 
output and stroke volume after the first procedure were signifi-
cantly greater than the values for these variables after the second 
procedure (4.4 ± 1.1 vs. 3.8 ± l.lliters/minj p < 0.05; and 54 ± 
17 vs. 47 ± 15 mllbeatj p < 0.05, respectively). There were no 
significant differences in the change observed in any variable 
between the first and second procedures. 
At a mean follow-up interval of 5.3 months (range 6 days to 15 
months) after the second procedure 18 (38%) of the 47 patients 
had died, 12 (25%) required surgical valve replacement and 4 
(8%) required a third valvuloplasty procedure. Overall, 31 (66%) 
In 1986, Cribier et al. (I) first described the technique of 
balloon aortic valvuloplasty for the treatment of adult ac-
quired aortic stenosis (I). At first, this procedure was touted 
as an alternative to aortic valve replacement, but very 
quickly it was recognized that the indications for it were 
fairly limited (2-4). Recent reports (5-8) have suggested that 
balloon aortic valvuloplasty in adults may be a reasonable 
therapeutic option primarily in patients with otherwise pro-
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of 47 patients met clinical failure end points after the second 
procedure. Three patients had two failure end points. 
The 47 patients were divided into two groups on the basis ofthe 
interval between valvuloplasty procedures. Of the 21 patients who 
underwent repeat valvuloplasty <6 months after the first proce-
dure, 7 patients (33%) died, 10 (48%) required aortic valve 
replacement and 1 (5%) required a third valvuloplasty procedure. 
A total of 17 (81 %) of the 21 patients met clinical failure end 
points. Of the 26 patients with repeat valvuloplasty 2::6 months 
after the original procedure, 11 (42%) died, 2 (8%) required 
surgical aortic valve replacement and 3 (11 %) required a third 
valvuloplasty procedure. A total of 14 (54%) of these 26 patients 
met clinical failure end points (p = 0.055 in comparison with 
patients with early repeat valvuloplasty). 
Balloon aortic valvuloplasty is a short-term palliative proce-
dure. When the palliative aspects of the procedure have failed, 
another palliative procedure is possible, but it is no better than the 
first. Patients undergoing a second procedure have a substantial 
rate of subsequent clinical failure, which may be even more likely 
if the interval between procedures is short. 
(J Am Coil CardioI1991;17:1430-S) 
hibitive surgical risk. Considerable controversy has arisen as 
this technique has been applied to younger less severely 
disabled patients (9-13). 
Balloon aortic valvuloplasty appears to be an effective 
procedure, at least in the short term. Numerous reports (1-7) 
document a significant lessening of symptoms and improve-
ment in hemodynamics immediately after valvuloplasty. The 
changes in valve area are modest, but appear to be sufficient 
for symptomatic improvement, at least initially. Unfortu-
nately, follow-up data have suggested a significant rate of 
restenosis and subsequent clinical failure (6-8). An unan-
swered question confronting the clinician is whether patients 
who present with restenosis should be considered for repeat 
valvuloplasty. 
There are a few anecdotal reports (6,7) on the use of 
mUltiple balloon aortic valvuloplasty procedures, but to date 
there has been no systematic documentation of the results of 
a second valvuloplasty procedure. The purpose of the 
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present study was to determine the efficacy of repeat balloon 
aortic valvuloplasty procedures. 
Methods 
Study patients. All patients in this study were enrolled in 
the Mansfield Scientific Aortic Valvuloplasty Registry, 
which comprised 492 patients entered between December 
1986 and November 1987 who underwent balloon aortic 
valvuloplasty at 27 clinical sites. Forty-seven patients, 18 
men and 29 women, were identified who had undergone a 
repeat valvuloplasty procedure. The mean age was 77 ± 10 
years; 75% of the patients were :;:::.75 years old, and most 
were considered poor surgical candidates because of ad-
vanced age or associated medical illness, or both. All were 
symptomatic, typically in functional class III or IV. The 
mean interval between the first and second valvuloplasty 
procedures was 6.4 months (range 2 days to 15 months). 
Valvuloplasty technique. Balloon aortic valvuloplasty 
was performed using the previously described retrograde 
arterial technique (1-7). The initial valvuloplasty procedures 
included 33 single balloon and 14 double balloon dilations; 
the repeat procedures included 35 single balloon and 12 
double balloon dilations. The balloon sizes used for the first 
and second procedures are discussed later. 
Registry data. The data consisted of clinical variables 
(age, gender, baseline clinical status, high risk characteris-
tics), procedural hemodynamic variables (mean pressure 
gradient, valve area, heart rate, stroke volume and cardiac 
output before and after the first and second procedures, time 
between procedures, balloon size), and follow-up variables 
(clinical status, time to follow-up). 
Efficacy. Efficacy was defined iri terms of both immediate 
procedural results and clinical failure end points. The hemo-
dynamic variables used to assess immediate procedural 
results included mean pressure gradient across the aortic 
valve, heart rate, stroke volume, cardiac output and aortic 
valve area (calculated utilizing the Gorlin equation [14]). 
Values were obtained before and after the first and second 
procedures. In addition, the change in each variable 
achieved by the first and second procedures was calculated. 
Follow-up and end points. The clinical failure end points 
were: 1) surgical aortic valve replacement, 2) a third proce-
dure, or 3) death. The mean duration of follow-up for 
patients undergoing repeat valvuloplasty was 11.4 ± 5.4 
months after the first procedure and 5.3 ± 4.2 months after 
the second procedure. Early clinical failure (restenosis) was 
empirically defined as a repeat procedure within 6 months of 
the original procedure. 
Statistical analysis. Pre procedure variables were com-
pared for the first and second procedures by a paired t test. 
A similar comparison was made of the postprocedure vari-
ables for the first and second procedures. Next, the changes 
in each variable achieved by the first procedure were com-
pared with the changes after the second procedure by a 
paired t test. Finally, the frequency of clinical failure end 
Table 1. Baseline Variables in 492 Patients 
Repeat BAV No Repeat BA V 
(n = 47) (n = 445) 
Age (yr) 77 ± IO 79 ± 8 
% Male 38% 45% 
Baseline NYHA class 
I 5% 4% 
II 22% 14% 
III 39% 46% 
IV 34% 36% 
High risk characteristics 
Advanced age 85% 87% 
Coexisting medical condition 62% 69% 
Severe ventricular dysfunction 34% 29% 
Severe CAD 17% 23% 
Surgery declined 28% 30% 
BAV = balloon aortic valvuloplasty; CAD = coronary artery disease; 
NYHA = New York Heart Association. 
points was compared in the early and late resteriosis groups 
by a chi-square test. Statistical significance was defined as a 
p value <0.05. 
Results 
Baseline clinical data. Table 1 shows a comparison of 
baseline clinical data on the 47 patients who underwent 
repeat procedures and the 445 patients (from the original 
cohort of 492 patients) who did not undergo a repeat valvu-
loplasty. There were no major differences between the two 
groups although there were slightly (but not significantly) 
fewer men in the repeat valvuloplasty group. Patients under-
going repeat procedures were not significantly youI1ger and 
had similar baseline functional status and high risk charac-
teristics to those of patients not undergoing a second proce-
dure. 
Balloon sizes. Table 2 shows the balloon sizes used for 
the first and second valvuloplasty procedures. Slightly larger 
balloon sizes were used in the second procedure. This was 
true regardless of how single balloon equivalents of double 
balloon dilations were calculated, using either the sum of the 
two areas (p < 0.01) or the maximal circumference (p < 
0.05). 
Hemodynamic variables before and after the first and 
second valvuloplasty procedures (Table 3). There were sig-
nificant (p < 0.001 and p < 0.05, respectively) differences in 
the mean pressilre gradient across the aortic valve before 
the first (62 ± 21 mm Hg) versus before the second (53 ± 
21 mm Hg) valvuloplasty procedure and after the first (32 ± 
13 mm Hg) versus after the second (28 ± 14 mm Hg) 
valvuloplasty procedure. The pressure gradient data for the 
47 patients undergoing repeat valvuloplasty at the four time 
points (before and after the first and second procedures) are 
shown in Figure 1. The 445 patients not undergoing repeat 
valvuloplasty had similar valve areas and gradients before 
and after valvuloplasty (valve area 0.5 ± 0.2 vs. 
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Table 2. Balloon Sizes Used for the First and Second 
Valvuloplasty Procedures in 47 Patients 
BAV 1 BAV 2 
Single balloon 
15 
18 4 
20 27 8 
23 2 22 
25 I 
Total 33 35 
Double balloon 
15115 8 3 
10/20 
12120 3 
15118 3 
15/20 5 
18120 
Total 14 12 
Mean size I' 20.6 ± 1.9 22.2 ± 2.0 
Mean size 2t 21.6 ± 3.2 23.1±3.0 
'Single balloon equivalent of double balloons calculated as sum of areal + 
area2; P < 0.01 BA V 1 versus BAV 2. tSingle balloon equivalent of double 
balloons calculated as maximal circumference; p < 0.05 BAV 1 versus BA V 
2. Abbreviations as in Table I. 
0.8 ± OJ cm2; mean pressure gradient 60 ± 23 vs. 29 ± 
13 mm Hg). 
The cardiac output after the first valvuloplasty procedure 
(4.4 ± 1.3 liters/min) was significantly (p < 0.005) greater 
than that after the second procedure (3.8 ± 1.1 liters/min) 
(Fig. 2). Additionally, stroke volume was significantly (p < 
0.01) greater after the first (54 ± 17 m!) versus the second 
procedure (47 ± 15 m!) (Fig. 3). Cardiac output and stroke 
volume before the two procedures were not significantly 
different. Calculated aortic valve area and heart rate before 
and after the first and second procedures were also not 
significantly different. 
Table 3. Hemodynamic Results for 47 Patients Undergoing 
Repeat Balloon Aortic Valvuloplasty 
BAV 1 BAV 2 
Aortic valve area (cm2) 
Pre 0.5 ± 0.2 0.5 ± 0.2 
Post 0.8 ± OJ 0.8 ± OJ 
Mean pressure gradient (mm Hg) 
Pre 62 ± 21 53 ± m 
Post 32 ± 13 28 ± 14* 
Cardiac output (liters/min) 
Pre 4.2 ± 1.4 3.9 ± 1.1 
Post 4.4 ± 1.3 3.8 ± l.It 
Heart rate (beats/min) 
Pre 81 ± 17 82 ± 14 
Post 81 ± 13 84 ± 14 
Stroke volume (m!) 
Pre 52 ± 18 49 ± 16 
Post 54 ± 17 47 ± 15t 
*p < 0.05 versus BAV 1; tp < 0.01 versus BAV 1; +p < 0.005 versus BA V 
1; §p < 0.001 versus BAV I. Abbreviations as in Table I. 
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Figure 1. Mean pressure gradient (mm Hg) across the aortic valve in 
47 patients at four time points: pre-l (before the first balloon aortic 
valvuloplasty procedure), post-l (after the first procedure), pre-2 
(before the second procedure) and post-2 (after the second proce-
dure). The gradients before and after the first procedure were 
significantly higher than the gradients before and after the second 
procedure (p < O.OOl and p < 0.05. respectively). 
The changes in heart rate, cardiac output, stroke volume, 
mean pressure gradient and valve area that resulted from 
the first and second procedures are compared in Table 4. 
The only significant differences in the change observed in 
any variable between the first and second procedures was a 
slightly lower decrease in mean gradient by the second 
valvuloplasty procedure. There were no other significant 
differences between the results achieved by the first and 
second procedures. The 445 patients not undergoing repeat 
valvuloplasty also had similar changes in aortic valve area 
(OJ ± 0.2 cm2) and mean pressure gradient (30 ± 18 mm 
Hg). Follow-up functional status of living patients who 
underwent repeat valvuloplasty in comparison with that of 
living patients not undergoing repeat valvuloplasty is shown 
in Table 5. Patients who required a second valvuloplasty 
Figure 2. Cardiac output (liters/min) in 47 patients at the four time 
points shown in Figure I. Cardiac output values after the first 
valvuloplasty procedure were significantly higher than values after 
the second procedure (p < 0.005). 
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Figure 3. Stroke volume (m\) in the 47 patients at the four time 
points shown in Figures 1 and 2. Stroke volume values after the first 
valvuloplasty procedure were significantly higher than those after 
the second procedure (p < 0.01). 
procedure had slightly worse functional status (46% in class 
III or IV) in comparison with the group not undergoing a 
second procedure (29% in class III or IV). 
Clinical follow-up end points of the 47 patients undergoing 
repeat aortic valvuloplasty (Table 6). Eighteen (38%) of the 
47 patients died, 12 (25%) required surgical valve replace-
ment and 4 (8%) required a third valvuloplasty procedure. 
Overall, 31 patients (66%) met clinical failure end points at a 
mean follow-up interval of 5.3 months after the second 
procedure (range 6 days to 15 months); 3 patients had two 
failure end points. In comparison, of the 445 patients not 
undergoing repeat aortic valvuloplasty, 33% had died and 
only 11% had undergone surgical valve replacement a mean 
of 8.5 ± 4 months after the initial procedure. 
Patients undergoing repeat aortic valvuloplasty were then 
classified into two groups on the basis of the time interval 
between valvuloplasty procedures. Repeat valvuloplasty <6 
months after the first procedure was empirically defined as 
an early procedure. Follow-up of these two groups of 
patients is also shown in Table 6. 
In Group I (those who underwent an early repeat valvu-
loplasty procedure) 7 (33%) of 21 patients died, 10 (48%) 
required surgical valve replacement and 1 patient (5%) 
required a third valvuloplasty procedure. In Group II (those 
who received a late repeat valvuloplasty procedure), 11 
(42%) of 26 patients died, 2 (8%) required surgical aortic 
Table 4. Changes in Hemodynamic Variables for 47 Patients 
Undergoing Repeat Balloon Aortic Valvuloplasty 
BAV I BAV 2 
Aortic valve area (cm2) OJ :t:: 0.2 OJ :t:: OJ 
Mean pressure gradient (mm Hg) -30:t:: 16 -25 ± 16* 
Cardiac output (liters/min) 0.2 :t:: 0.9 -0.1 ± 0.6 
Heart rate (beats/min) 0.2 :t:: 0.9 203 :t:: 9.8 
Stroke volume (mll 2.0 ± 12.0 -1.0 ± 9.0 
*p < 0.05. BA V 2 versus BAV I. Abbreviations as in Table I. 
Table 5. Follow-Up Functional Status 
Repeat BAV No Repeat BA V 
(n = 22) (n = 242) 
NYHA classification* 
Class I 18% 29% 
Class II 36% 42% 
Class III 23% 24% 
Class IV 23% 5% 
CHF at last follow-up. 35% 31% 
*p < 0.05 by chi-square analysis. CHF = congestive heart failure; other 
abbreviations as in Table I. 
valve replacement and 3 (11 %) required a third valvuloplasty 
procedure. Thus, 17 (81%) of 21 patients in Group I (early 
restenosis) met clinical failure end points compared with 
only 14 (54%) of 26 patients in Group II (late restenosis) (p = 
0.055). 
One potential concern is that patients in Group I may 
represent patients with inadequate valve dilation. We there-
fore compared hemodynamic variables for the first and 
second procedures between Group I and Group II (Table 7). 
There was no significant difference between the two groups 
in any of the pre- or postprocedure hemodynamic variables 
or in the hemodynamic changes resulting from either the first 
or the second procedure. 
Discussion 
Aortic valve replacement remains the treatment of choice 
for patients with acquired aortic stenosis and an acceptable 
surgical risk. Balloon aortic valvuloplasty has emerged as an 
alternative therapeutic option available for selected high risk 
patients with critical aortic stenosis. Reports from various 
groups (1-7) have demonstrated the immediate efficacy of 
balloon valvuloplasty in this patient group from the stand-
point of hemodynamic improvement and palliation of symp-
toms. However, at follow-up there is a significant rate of 
restenosis, with a 1 year event-free (recurrent symptoms or 
death) survival rate of approximately 50% (6). Given a 
relatively high rate of valvular restenosis, an issue that is 
being confronted with increasing frequency is how to treat 
Table 6. Clinical Follow-Up Status of 47 Patients 
End point All Patients Group I Group II 
(n = 47) (n = 21) (n = 26) 
Death 18 (38%) 7 (33%) II (42%) 
Aortic valve replacement 12 (25%) 10 (48%)* 2 (8%)t 
Third BA V procedure 4 (8%) 1(5%) 3 (11%)t 
Total 31147 17/21 14/26 
(66%) (81%) (54%) 
*One patient in Group I died after aortic valve replacement; tone patient 
in Group II died after aortic valve replacement; tone patient in Group II died 
after a third balloon aortic valvuloplasty procedure. Group I = repeat 
valvuloplasty <6 months after the first procedure; Group 2 = repeat valvu-
loplasty 2:6 months after the first procedure. Abbreviations as in Table I. 
1434 FERGUSON ET AL. 
REPEAT BALLOON AORTIC VALVULOPLASTY PROCEDURES 
JACC Vol. 17, No.6 
May 1991:1430-5 
Table 7. Comparisons of Hemodynamic Variables by Groups 
BAV I BAV 2 
Group I Group II Group I Group II 
Aortic valve area (cm2) 
Pre 0.5 ± 0.2 0.5 ± 0.2 0.6 ± 0.1 0.5 ± 0.2 
Post 0.8 ± 0.2 0.8 ± OJ 0.9 ± 0.4 0.7 ± 0.2 
Mean pressure gradient (mm Hg) 
Pre 59 ± 16 64 ± 24 47 ± 16 58 ± 24 
Post 31 ± 11 32 ± 14 25 ± 14 31 ± 14 
Cardiac output (liters/min) 
Pre 4.5 ± 1.7 3.9 ± 1.1 3.9 ± 1.1 3.8 ± 1.2 
Post 4.5 ± 1.4 403 ± 1.2 3.9 ± 0.9 3.7 ± 1.2 
Heart rate (beats/min) 
Pre 81 ± 19 81 ± 14 82 ± 17 82 ± II 
Post 82 ± 16 80 ± 11 81 ± 15 87 ± 13 
Stroke volume (ml) 
Pre 57 ± 21 49 ± 15 50 ± 15 48 ± 18 
Post 55 ± 18 53 ± 16 50 ± 15 43 ± 16 
Group I and Group II are defined in Table 6. Abbreviations as in Table 1. 
patients who develop stenosis recurrence after their initial 
procedure. 
Reported results of repeat valvuloplasty for restenosis. 
Safian et al. (6) recently reported their results in 170 consec-
utive patients, 16 of whom underwent a repeat procedure. 
They found the outcome of a second procedure to be 
generally similar to that of the original procedure in terms of 
changes in valve area and mean pressure gradient. They 
suggested that repeat balloon aortic valvuloplasty is an 
option in patients who develop restenosis. Outcome after the 
second procedure was not reported. 
Letac et al. (7) also recently reported their large series of 
218 patients undergoing aortic valvuloplasty, 21 of whom 
underwent redilation for restenosis. Again, they found that 
the second procedure achieved changes in gradient and 
valve area that were similar to those of the first procedure. 
No follow-up data on the second procedure were reported. 
Results of the present study. Our data confirm that the 
hemodynamic results of the second aortic valvuloplasty 
procedure were similar to those of the initial procedure, at 
least in terms of the changes achieved in valve area and 
gradient. The more complex question that remains relates to 
the appropriate choice of patients for repeat valvuloplasty as 
opposed to surgical valve replacement. Although repeat 
valvuloplasty may be as efficacious as the original proce-
dure, in patients who have little hemodynamic benefit or 
early restenosis after the first procedure, a second procedure 
may be as ineffective as the original. Thus a second proce-
dure appears to be neither worse nor better than the first 
with respect to the immediate hemodynamic results. 
Repeat procedures are associated with a high rate of 
subsequent clinical failure. There appears to be a tendency 
for more subsequent clinical failure when patients undergo-
ing a second procedure are compared with patients who did 
not require a second procedure. Sixty-six percent of our 47 
patients who underwent repeat aortic valvuloplasty met hard 
clinical failure end points after the second procedure in 
comparison with 44% of the original cohort who did not 
require a second procedure. Obviously, however, there is 
some selection bias in any such comparison with a skewed 
population of patients who have already demonstrated a 
propensity for clinical failure after balloon aortic valvulo-
plasty. 
Additionally, our data suggest that patients who have 
early restenosis and undergo an early second procedure 
(arbitrarily defined as occurring in ::;6 months of their initial 
valvuloplasty procedure) have a greater tendency (p = 
0.055) for subsequent clinical failure in comparison with 
patients undergoing a late (>6 months) second procedure. 
Analysis of the follow-up functional status of early versus 
late repeat procedures will require a larger number of 
patients for valid statistical analysis. 
The question arises as to whether there is some sort of 
selection bias in choosing repeat valvuloplasty over other 
therapy. Patients undergoing repeat valvuloplasty were not 
significantly younger, and had a pre valvuloplasty functional 
status similar to that of patients who did not require repeat 
valvuloplasty. There were slightly (but not significantly) 
more women in the repeat valvuloplasty group, which may 
be a reflection of a reticence to operate on elderly women. 
There was no difference in high risk characteristics of the 
repeat valvuloplasty group, and no suggestion that repeat 
valvuloplasty was chosen because of the success or failure of 
the initial procedure. 
Implications. One obvious implication of our results is 
that patients with failed valvuloplasty do not do well after a 
repeat valvuloplasty procedure when a second intervention 
becomes necessary. The high likelihood of subsequent clin-
ical failure after a second valvuloplasty procedure must be 
weighed against the relatively high surgical risk for these 
patients, especially those who develop restenosis within 6 
months. We believe that patients who develop early resteno-
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sis warrant surgical valve replacement, if possible, despite 
their high surgical risk, whereas those developing late re-
stenosis may do well with a second valvuloplasty procedure. 
Conclusions. Balloon aortic valvuloplasty is a short-term 
palliative procedure. When the palliative aspects of the 
procedure have failed (restenosis with recurrence of symp-
toms), another palliative procedure is possible but it is no 
better than the first. If restenosis has developed over a 
relatively short period of time, the sustained, palliative 
benefit of a second procedure is limited. Patients with failed 
valvuloplasty may be better served with aortic valve replace-
ment despite their relatively high surgical risk. 
We acknowledge the invaluable assistance of Janet Bologna. Michelle Mich-
ela. and Sharon Cunningham from Mansfield Scientific Inc. in obtaining the 
Registry data, and Angie Ruiz at St. Luke 's/Texas Heart Institute for 
assistance in preparation of the manuscript. 
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